TY - JOUR T1 - Clinical Characteristics and Outcomes of Diabetic COVID-19 patients in Kuwait JF - medRxiv DO - 10.1101/2020.08.20.20178525 SP - 2020.08.20.20178525 AU - Abdullah Alshukry AU - Mohammad Bu Abbas AU - Yaseen Ali AU - Barrak Alahmad AU - Abdullah A. Al-Shammari AU - Mohammad Abu-Farha AU - Jehad AbuBaker AU - Sriraman Devarajan AU - Ali A. Dashti AU - Fahd Al-Mulla AU - Hamad Ali Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/11/2020.08.20.20178525.abstract N2 - Background COVID-19 has a highly variable clinical presentation, ranging from asymptomatic to severe respiratory symptoms and death. Diabetes seems to be one of the main comorbidities contributing to a worse COVID-19 outcome.Objective In here we analyze the clinical characteristics and outcomes of diabetic COVID-19 patients.Methods In this single-center, retrospective study of 417 consecutive COVID-19 patients, we analyze and compare disease severity, outcome, associated complications, and clinical laboratory findings between diabetic and non-diabetic COVID-19 patients.Results COVID-19 patients with diabetes had more severe outcomes and higher mortality than non-diabetic COVID-19 patients. Diabetic COVID-19 patients had significantly higher prevalence of comorbidities, such as hypertension. Laboratory investigations also highlighted notably higher levels of C-reactive protein in diabetic COVID019 patients and lower estimated glomerular filtration rate. They also showed a higher incidence of complications.Conclusion Diabetes could be a major contributor to worsening outcomes in COVID-19 patients. Understanding the pathophysiology underlining these findings could provide insight into better management and improved outcome of such cases.Highlights of the StudyA significantly higher proportion of Diabetic COVID-19 patients required admission to the ICU.Higher fasting blood glucose was associated with higher risk of COVID-19 associated mortality.Diabetic COVID-19 patients had significantly higher incidence of complications including sepsis, ARDS, cardiac failure and renal failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was obtained for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Standing Committee for Coordination of Health and Medical Research at the Ministry of Health in Kuwait reviewed and approved this retrospective study (Institutional Review Board 2020/1404). The Standing Committee waived the requirement for written informed consent because of the urgency of data collection and the exceptional nature of the disease. All procedures involving human participants were performed following the relevant guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented in this study was made available on springer nature data depository.https://doi.org/10.6084/m9.figshare.12567881.v1. ER -